YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here. In Q3 2026, Cedar Grove Capital Management's Multi-Strategy Composite returned -1…
Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug. Continue Reading
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves. NKTR is down 19.1% at $48.97…
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news…
A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co.(NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Mil…
Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) shares rose 3.6% in premarket trading Friday following a jury verdict awarding the company $90 million in damages in a contract dispute with Eli Lilly and Company (NYSE:LLY). Still guessin…
Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Digital Justice and Legal Tech Concept with Scales of Justice Icon and Circuit Network] jittawit.21/iStock via Getty Images Nektar Therapeutics (NKTR [https://seekingalpha.com/symbol/NKTR]) quickly sank 11% as a jury deliberated in its pa…
On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 tr…
Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per sha…
Wall Street is headed for a winning week in which the S&P 500 has recorded a new all-time high. The Department of Commerce reported that retail sales decreased 0.6% in July. The Zacks Consensus Estimate was for a breakeven. The metric for…
Wall Street is headed for a winning week in which the S&P 500 has recorded a new all-time high. The Department of Commerce reported that retail sales decreased 0.6% in July. The Zacks Consensus Estimate was for a breakeven. The metric for…
Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (…
[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consum…
Nektar Therapeutics NKTR announced that it has initiated the first two registrational studies in the phase III ZENITH AD program, which is evaluating its pipeline candidate, rezpegaldesleukin (rezpeg), for treating moderate-to-severe atopi…
(RTTNews) - "The secret to investing is to figure out the value of something - and then pay a lot less", according to Joel Greenblatt, an American investor, hedge fund manager, and author of The Little Book That Beats the Market. The follo…
Howard W. Robin, President & CEO of Nektar Therapeutics (NASDAQ:NKTR), disclosed the sale of 20,000 shares in multiple open-market transactions on June 16 and June 17, 2026, for a total value of approximately $1.22 million, according to a…
Quick Read AbbVie (ABBV) proved big pharma will pay up for late-stage immunology with the Apogee deal, reigniting M&A speculation across the biotech sector. Syndax (SNDX) earns the top takeover ranking with two FDA-approved drugs, 224% rev…
Nektar Therapeutics (NASDAQ:NKTR) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Wedbush analyst Martin Fan decreased the price target on Nektar Therapeutics (NASDAQ:NKTR) from $95 to $80 whi…
[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell…
On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of Nektar Therapeutics(NASDAQ:NKTR), an estimated $10.27 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi…
Key Points Prosight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter. The value of the firm’s Nektar Therapeutics position rose…
Key Points Prosight bought 468,463 shares of GeneDx Holdings, estimated at $42.72 million based on average first-quarter 2026 prices. The quarter-end value of the position rose by $26.46 million, reflecting both trading and price moves. Th…
On May 15, 2026, Prosight Management disclosed a purchase of 468,463 shares of GeneDx Holdings(NASDAQ:WGS), an estimated $42.72 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi…
What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics(NASDAQ:NKTR). The estimated value of the trade was $…
Nektar Therapeutics NKTR reported a loss of $1.82 per share for the first quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.74. In the year-ago quarter, the company had reported a loss of $3.62 cents per share. Total…
Earnings Call Insights: Nektar Therapeutics (NKTR) Q1 2026 MANAGEMENT VIEW * “Supported by these results, we're moving quickly to initiate the ZENITH-AD Phase III program in patients with moderate to severe atopic dermatitis by July of thi…
LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherw…
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Nektar Therapeutics (NASDAQ: NKTR) promised investors a rigorously controlled Phase 2b clinical trial. The results told a different story. Find out if you can recover your investment losses or con…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options If you purchased or acquired Nektar securities between February 26, 20…
NEW YORK, May 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive…
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeuti…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options If you purchased or acquired Nektar securities between February 26, 20…